stars 1 stars 2 stars 3

Created from work carried out by three research experts, Alvéole’s goal is to make the control of living cells the future of cell biology. A company specialized in devices for controlling the cellular microenvironment, Alvéole presents its first device PRIMO. Alvéole was founded in 2010 by three researchers from CNRS* in collaboration with Quattrocento, a “creator of young innovative companies” in the life sciences field that allows academic researchers to transform their inventions into commercial products. Vincent Studer (a specialist in bio-engineering), Maxime Dahan (a specialist in cell imaging), and Jean-Christophe Galas (a specialist in nanostructures) have collaborated since 2008 to develop tools for research in cell biology. In 2010, Quattrocento founded Alvéole, with their collaboration. *Vincent Studer, the Neurosciences Interdisciplinary Institute (CNRS, University of Bordeaux). Maxime Dahan, the Curie Physics and Chemistry Unit, (CNRS, Curie Institute, Pierre and Marie Curie University). Jean-Christophe Galas, the Jean Perrin Laboratory, (CNRS, Pierre and Marie Curie University).

Alvéole Questions

The Alvéole annual revenue was $3 million in 2026.

Helene Delobel is the COO of Alvéole.

4 people are employed at Alvéole.

Alvéole is based in Paris, Ile-de-France.

The NAICS codes for Alvéole are [541713, 54, 54171, 541, 5417].

The SIC codes for Alvéole are [873, 87].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users